


EMLc


ATC codes: [L01AX04](#)

Indication	Hodgkin lymphoma <span>ICD11 code: <a href="#">2C10.Z</a></span>
INN	Dacarbazine
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 100 mg in vial powder for injection
EML status history	First added in 1989 ( <a href="#">TRS 796</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2011 ( <a href="#">TRS 965</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 


Tags

Cancer

Wikipedia

[Dacarbazine](#) 

DrugBank

[Dacarbazine](#) 

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dacarbazine on the complementary list of the EML for use in treatment protocols for Hodgkin lymphoma was specifically endorsed and it was added to the complementary list of the EMLc for this indication. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Hodgkin lymphoma in adults and in paediatrics are attached.

[Expert Committee report](#) 

